Navigation Links
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Date:9/15/2008

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel

macrolide-related drug class

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Preclinically, EDP-322 has demonstrated strong in vitro activity against hospital-acquired MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

"Macrolides have been commonly prescribed to treat community infections for decades due to their convenient oral dosing and favorable safety profile," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now with the discovery of a new generation of macrolides having high potency against hospital-acquired pathogens and a distinct resistance profile relative to other hospital antibiotics, there is a tremendous new opportunity to explore their use within not only the community, but the hospital setting as well."

"In our in vitro studies, EDP-322 demonstrated good potency against both hospital- and community-acquired MRSA, even against highly drug-resistant MRSA strains," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "The potency of EDP-322 against hospital-acquired MRSA, community-acquired MRSA, and other gram-positive pathogens, combined with the convenience of oral administration, has the potential to uniquely position EDP-322 among marketed MRSA drugs in both the hospital and community settings."

Phase 1a Study Design

The Phase 1a, double-blind, placebo controlled study for EDP-322 announced today is a single ascending dose trial in healthy volunteers.

About Enanta's Bicyclolide Research Program

Bicyclolides posses a reengineered back-bone structure of traditional macrolide antibiotics. The discovery of Bicyclolide effectiveness against MRSA and VRE infections is part of Enanta's broad antibiotic research program. Enanta has applied several research strategies to develop these new classes of antibiotics, including innovative medicinal chemistry approaches to create novel and proprietary chemical structures. Enanta has applied its chemistry approach to create a promising pipeline of anti-infective drugs and a vast intellectual property estate.

About MRSA

More than 130,000 people each year need hospital care for MRSA infections, according to the Centers for Disease Control and Prevention. Staphylococcus aureus is a bacterium that can live harmlessly on human skin and is found in the nose of 20 to 40 percent of healthy individuals, but can sometimes cause infections when exposed to broken skin. MRSA is a particular type of the bacteria that has developed resistance to many antibiotics, including methicillin, making it difficult to treat.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease, polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at http://www.enanta.com.

Zyvox is a registered trademark of Pfizer Inc. and CUBICIN is a registered trademark of Cubist Pharmaceuticals, Inc.

Enanta Contacts

For Enanta Investor Relations, please contact:

Paul Mellett

617-607-0761

For Enanta Public Relations, please contact MacDougall Biomedical Communications:

Kari Watson

781-235-3060

kwatson@macbiocom.com


'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
7. Isis Initiates Clinical Trial of CRP Drug
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
10. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):